Table 1.

Clinical profiles of SCLS subjects.

Pt no.	Age at Diagnosis*	Sex	Ethnicity	Attack Frequency	Current Treatment Regimen	MGUS
1	45	M	C	Every 4–6 weeks	IVIG	IgG kappa
2	49	F	C	Weekly/monthly	IVIG	IgG kappa
3	45	M	C	Every weekend	Infliximab	IgA kappa
4	55	M	C	> 2/yr	IVIG	IgG kappa
5	46	F	C	5–10 day intervals	N/A (deceased)	IgG lambda
6	42	M	C	3–4 year intervals	Theophylline	IgG kappa
7	32	M	C	3–5 year intervals	IVIG	IgG kappa
8	59	M	C	Single episode	None	IgG kappa
9	65	M	C	3–4/year	IVIG	IgG kappa
10	39	F	C	Chronic	T/T**	ND#
11	48	F	C	Infrequent	T/T	IgG lambda
12	48	M	C	weekly	IVIG	IgG kappa
13	50	F	C	> 2x/yr	IVIG	IgG kappa
14	51	M	C	> 2x/yr	IVIG	IgG
15	53	M	C	Weekly	IVIG	IgG lambda
16	40	F	C	Chronic	Theophylline	IgG kappa
17	43	F	C	3–4 year interval	None	IgG kappa
18	64	F	C	Chronic	Theophylline	IgG kappa
19	48	M	AA	3–4/yr	IVIG	IgG lambda
20	43	M	C	Bimonthly	IVIG	IgG kappa
21	65	M	C	Single episode	Theophylline	IgG kappa
22	43	M	C	< 2x/yr	IVIG	IgG kappa
23	36	F	C	< 2x/yr	IVIG	IgG kappa
24	66	M	C	< 2x/yr	IVIG	IgG lambda
25	40	F	C	Single episode	IVIG	IgG kappa
26	62	M	C	< 2x/yr	IVIG	IgG kappa
27	7	F	C	Chronic plus acute	Subcutaneous IG	ND#
28	48	M	C	< 2x/yr	IVIG	IgG lambda
29	61	M	C	3–4 year intervals	IVIG	IgG kappa
30	43	F	C	< 2x/yr	IVIG	IgG lambda
31	58	F	C	Chronic plus acute	None	IgM kappa
32	33	M	C	< 2x/yr	IVIG	ND#
33	37	F	C	Chronic plus acute	IVIG	ND#
34	22 mo.	F	C	Every 5–6 months		ND#
35	8	C	C	Weekly	IVIG	ND#

^*Note: Many patients experienced episodes consistent with SCLS prior to formal diagnosis;

^**: Theophylline plus terbutaline;

^#: Not detected